multiple myeloma
Natera Q1 Revenues Grow 62 Percent
The company reported $152.3 million in total revenues for the quarter and said the number of tests it processed rose 48 percent from the prior-year quarter.
Sebia, Netherlands Universities to Develop Test for Disease Status in Patients With Multiple Myeloma
The organizations said the test will determine and monitor the status of patients using an innovative blood-based mass spectrometry laboratory assay.
Adaptive Biotechnologies Q4 Revenues Rise 41 Percent
Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.
SkylineDx Partners With German Hospital to Assess Multiple Myeloma Test
The study's goal is to measure the success rate of SkylineDx's multiple myeloma test in a real-world setting compared to the hospital's current standard.
Sebia to Develop Dx Test for Sanofi Multiple Myeloma Treatment
The IVD test will adjust for isatuximab-induced interference in immunofixation electrophoresis tests, which can mislead clinicians in interpreting patient response.Â